Merit Medical Systems, Inc. (MMSI)
NEUTRALFundamental
72
Precio
$91.70
Capitalización Bursátil
$5.42B
Parte 1 · Cuánto vale la empresa
Resumen
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$1.58B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$146M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$216M
Patrimonio Neto Total
$1.58B
Pasivo Total
$1.10B
Ratio de Liquidez
4.20
Cobertura de Intereses
6.34
Deuda/EBITDA
2.66
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$74.50
Precio Actual
$91.70
Margen de Seguridad
-23.1%
Rango de Valor Justo
$48.43 - $100.58
Métodos de Estimación
Métricas de Valoración
Ratio P/E
37.15
ROE
8.1%
Ratio P/B
3.21
P/FCF
26.53
Margen Bruto
49.5%
ROIC
6.1%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
6.1%
WACC
7.3%
ROIC − WACC
-1.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (21)
- EPS shows upward trend
- EPS CAGR 7.91%
- Price CAGR 13.10%
- ROIC 6.1%
- Gross Margin 49.5%
- P/FCF 26.53
- Debt/Equity ratio
- Operating Margin 12.8%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 9.1%
- Revenue Growth 5Y 9.5%
- Analyst Consensus 82% Buy
- Earnings Surprise avg 11.9%
- Earnings Quality (OCF/NI) 1.95
- Share Dilution 1.7%
- Net Margin Trend 9.2% vs 8.3%
- Piotroski F-Score 7/9
Fallido (5)
- P/B Ratio 3.21
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
No disponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Solidez financiera fuerte
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
El número de acciones es estable
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Ms. Martha Goldberg Aronson | President, CEO & Director | 58 |
| Mr. Raul Parra Jr., CPA | CFO & Treasurer | 46 |
| Mr. Brian G. Lloyd J.D. | Chief Legal Officer & Corporate Secretary | 64 |
| Mr. Michel J. Voigt | Chief Human Resources Officer | 52 |
| Mr. Jason Treft | Chief Information Officer | - |
| Ms. Sarah Comstock | Vice President of Global Communications | - |
| Mr. John Knorpp | Chief Regulatory Affairs Officer | - |
| Mr. Ricardo Alvarez | Managing Director of Operation Merit Medical Tijuana | - |
| Mr. Mark Butler | Executive Vice President of Merit Medical EMEA | - |
| Ms. Alisha Jerauld | Sustainability Council Chair and Vice President of Environment, Social & Governance | - |
Riesgo de Auditoría
2
Riesgo del Consejo
2
Riesgo de Compensación
1
Riesgo de Derechos del Accionista
4
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for MMSI, sourced from Markets Gazette.